Article
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Hepatology (Baltimore, Md.) - 2 Sept 2011
Di Martino Vincent, Richou Carine, Cervoni Jean-Paul, Sanchez-Tapias Jose M, Jensen Donald M, Mangia Alessandra, Buti Maria, Sheppard Frances, Ferenci Peter, Thévenot Thierry
Abstract excerpt
UNLABELLED: Response-guided pegylated interferon (peg-IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus-infected patients provide contradictory results. We conducted meta-analyses of randomized, controlled trials to address (1) the benefit of a 72-week extended-duration therapy in G1-slow responders and (2) adequate shortened duration therapy in G1 and G2/G3-rapid responders....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.